Patents by Inventor Benjamin J Rankin

Benjamin J Rankin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8568792
    Abstract: A mixed metal compound for pharmaceutical use is free from aluminium and has a phosphate binding capacity of at least 30%, by weight of the total weight of phosphate present, over a pH range of from 2-8. The compound is especially useful for treatment of hyperphosphataemia. The metals are preferably iron (III) and at least one of calcium, magnesium, lanthanum and cerium. A metal sulphate for pharmaceutical use is selected from at least one of calcium, lanthanum and cerium sulphate compounds and has a phosphate binding capacity of at least 30% by weight of the total phosphate present, over a pH range from 2-8.
    Type: Grant
    Filed: July 1, 2010
    Date of Patent: October 29, 2013
    Assignee: Cytochroma Development Inc.
    Inventors: Norman B Roberts, Maurice Webb, Benjamin J Rankin
  • Publication number: 20110014301
    Abstract: A mixed metal compound for pharmaceutical use is free from aluminium and has a phosphate binding capacity of at least 30%, by weight of the total weight of phosphate present, over a pH range of from 2-8. The compound is especially useful for treatment of hyperphosphataemia. The metals are preferably iron (III) and at least one of calcium, magnesium, lanthanum and cerium. A metal sulphate for pharmaceutical use is selected from at least one of calcium, lanthanum and cerium sulphate compounds and has a phosphate binding capacity of at least 30% by weight of the total phosphate present, over a pH range from 2-8.
    Type: Application
    Filed: July 1, 2010
    Publication date: January 20, 2011
    Applicant: INEOS HEALTHCARE LIMITED
    Inventors: Norman B. Roberts, Maurice Webb, Benjamin J. Rankin
  • Patent number: 7799351
    Abstract: A mixed metal compound for pharmaceutical use is free from aluminium and has a phosphate binding capacity of at least 30%, by weight of the total weight of phosphate present, over a pH range of from 2-8. The compound is especially useful for treatment of hyperphosphataemia. The metals are preferably iron (III) and at least one of calcium, magnesium, lanthanum and cerium. A metal sulphate for pharmaceutical use is selected from at least one of calcium, lanthanum and cerium sulphate compounds and has a phosphate binding capacity of at least 30% by weight of the total phosphate present, over a pH range from 2-8.
    Type: Grant
    Filed: July 10, 2003
    Date of Patent: September 21, 2010
    Assignee: INEOS Healthcare Limited
    Inventors: Norman B. Roberts, Maurice Webb, Benjamin J. Rankin
  • Patent number: 6926912
    Abstract: A non-aluminum containing mixed metal compound for pharmaceutical use, which may, for example, be a mixed metal hydroxy carbonate containing magnesium and iron, and may have a hydrotalcite structure, preferably a non-aged hydrotalcite structure. Other metals, including, for example, calcium, lanthanum and cerium, may also be used. Metal sulphate compounds, especially calcium sulphate, lanthanum sulphate and/or cerium sulphate, compounds are also useful. The mixed metal compounds have a phosphate binding capacity of at least 30%, by weight, based on the test methods 1, 2 or 3, described in the specification, over a pH range from 3 to 7, such as from 2 to 8. The compound is especially useful in the treatment of hyperphosphataemia.
    Type: Grant
    Filed: September 18, 1998
    Date of Patent: August 9, 2005
    Assignee: Ineos Silicas Limited
    Inventors: Norman B Roberts, Maurice Webb, Benjamin J Rankin
  • Publication number: 20040105896
    Abstract: A mixed metal compound for pharmaceutical use is free from aluminium and has a phosphate binding capacity of at least 30%, by weight of the total weight of phosphate present, over a pH range of from 2-8. The compound is especially useful for treatment of hyperphosphataemia. The metals are preferably iron (III) and at least one of calcium, magnesium, lanthanum and cerium. A metal sulphate for pharmaceutical use is selected from at least one of calcium, lanthanum and cerium sulphate compounds and has a phosphate binding capacity of at least 30% by weight of the total phosphate present, over a pH range from 2-8.
    Type: Application
    Filed: July 10, 2003
    Publication date: June 3, 2004
    Applicant: Crosfield Limited
    Inventors: Norman B. Roberts, Maurice Webb, Benjamin J. Rankin